分子乳腺成像与数字乳腺断层摄影用于致密型乳腺筛查:Density MATTERS试验
这项前瞻性多中心试验纳入2978例致密型乳腺女性,比较DBT与DBT联合MBI的筛查效能。第一年DBT联合MBI的癌症检出率11.8‰ vs DBT 5.0‰,浸润性癌检出率7.7‰ vs 3.0‰;第二年联合MBI检出率9.3‰ vs 5.8‰,召回率13.8% vs 8.9%。结论:DBT联合MBI使浸润性癌检出增加2.5倍,第二轮回召率轻度增加。
要点
- 致密型乳腺女性补充MBI可提高癌症检出率,第一年增量6.7‰、第二年增量3.5‰。
- 仅MBI检出的29例癌症中72%为浸润性癌,中位大小0.9 cm,90%淋巴结阴性。
- 补充MBI后召回率升高,第一年8.6%→17.9%,第二年8.9%→13.8%。
核心结论
- DBT筛查中加入MBI使浸润性癌检出增加2.5倍,并在第二轮回合使召回率轻度增加。
研究设计与样本
- 前瞻性、多年、多中心试验,共5个中心,2017至2022年纳入2978例致密型乳腺女性,接受两轮年度DBT和MBI筛查。
关键影像表现/征象
- 仅MBI检出的29例癌症中,21例(72%)为浸润性癌,中位大小0.9 cm,26例(90%)淋巴结阴性,6例(20%)为晚期癌。
- 第一年间隔癌率为0.7‰(2/2978),第二年为0.8‰(2/2590)。
诊断标准与关键数值
- 第一年DBT癌症检出率5.0‰(15/2978),DBT联合患病筛查MBI为11.8‰(35/2978),增量检出率6.7‰(95%CI:4.2,10.6),P<.001。
- 第一年DBT浸润性癌检出率3.0‰(9/2978),DBT联合MBI为7.7‰(23/2978),浸润性癌增量检出率4.7‰(95%CI:2.7,8.1),P<.001。
- 第二年DBT癌症检出率5.8‰(15/2590),DBT联合发病筛查MBI为9.3‰(24/2590),增量检出率3.5‰(95%CI:1.7,6.8),P=.001。
- 第二年DBT浸润性癌检出率1.5‰(4/2590),DBT联合MBI为3.9‰(10/2590),浸润性癌增量检出率2.3‰(95%CI:0.9,5.3),P=.048。
- 第一年召回率DBT 8.6%(255/2978)vs DBT联合MBI 17.9%(534/2978),差值9.4%(95%CI:8.4,10.5);第二年DBT 8.9%(231/2590)vs DBT联合MBI 13.8%(356/2590),差值4.8%(95%CI:4.1,5.7)。
临床应用与阅片要点
- 对致密型乳腺女性,在DBT筛查基础上补充MBI可提高浸润性癌检出,增量检出率第一年6.7‰、第二年3.5‰。
- 补充MBI后召回率升高,第一年差值9.4%、第二年差值4.8%,阅片时需结合召回率变化综合评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Molecular breast imaging (MBI) relies on the functional uptake of a radiotracer, technetium 99m sestamibi, to reveal cancers that are occult on mammograms due to breast density. Purpose To assess the performance of screening MBI as a supplement to digital breast tomosynthesis (DBT) in women with dense breasts. Materials and Methods In this prospective, multiyear, multicenter trial from five sites, women with dense breasts were prospectively enrolled from 2017 to 2022 and underwent two annual screening rounds of DBT and MBI to assess the incremental cancer detection rate (CDR, reported as cancers per 1000 screenings) of supplemental MBI and to compare other performance metrics of DBT and MBI. Results A total of 2978 participants were included. Participants had a mean age of 56.8 years ± 9.3 (SD) and a mean lifetime Tyrer-Cuzick risk of 12.0% ± 7.9 (SD). At year 1, the CDR was 5.0‰ (15 of 2978 participants) with DBT and 11.8‰ (35 of 2978 participants) with DBT plus prevalence screening MBI (incremental CDR, 6.7‰ [95% CI: 4.2, 10.6]; P < .001); the invasive CDR was 3.0‰ (nine of 2978 participants) with DBT and 7.7‰ (23 of 2978 participants) with DBT plus prevalence screening MBI (invasive incremental CDR, 4.7‰ [95% CI: 2.7, 8.1]; P < .001). At year 2, the CDR was 5.8‰ (15 of 2590 participants) with DBT and 9.3‰ (24 of 2590 participants) with DBT plus incidence screening MBI (incremental CDR, 3.5‰ [95% CI: 1.7, 6.8]; P = .001); the invasive CDR was 1.5‰ (four of 2590 participants) with DBT and 3.9‰ (10 of 2590 participants) with DBT plus incidence screening MBI (invasive incremental CDR, 2.3‰ [95% CI: 0.9, 5.3]; P = .048). The year 1 recall rate was 8.6% (255 of 2978 participants) with DBT and 17.9% (534 of 2978 participants) with DBT plus prevalence screening MBI (difference, 9.4% [95% CI: 8.4, 10.5]). The year 2 recall rate was 8.9% (231 of 2590 participants) with DBT and 13.8% (356 of 2590 participants) with DBT plus incidence screening MBI (difference, 4.8% [95% CI: 4.1, 5.7]). Twenty-nine participants had cancers detected only with MBI: 21 (72%) had invasive cancers (median size, 0.9 cm), 26 (90%) had node-negative cancers, and six (20%) had advanced cancers. The interval cancer rate was 0.7‰ (two of 2978 participants) in year 1 and 0.8‰ (two of 2590 participants) in year 2. Conclusion The addition of MBI to DBT screening increased invasive cancer detection by 2.5-fold and modestly increased the recall rate at the second screening round. © RSNA, 2025 See also the editorial by Fowler in this issue.
引用
- Hruska CB, Hunt KN, Larson NB, et al. Molecular Breast Imaging and Digital Breast Tomosynthesis for Dense Breast Screening: The Density MATTERS Trial. Radiology. 2025. PMID: 40985829. doi:10.1148/radiol.243953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。